{"hands_on_practices": [{"introduction": "Effective management of benign liver tumors begins with an accurate diagnosis, yet the decision to pursue invasive testing like a biopsy is complex. This exercise places you in the role of the clinician, requiring you to apply a risk-benefit framework to hypervascular liver lesions where imaging may be equivocal. By working through these scenarios [@problem_id:4603363], you will practice the critical skill of weighing the diagnostic value of a biopsy against its potential harms, a cornerstone of safe and rational hepatobiliary practice.", "problem": "A clinician is deciding whether to perform a percutaneous core needle biopsy on a hypervascular liver lesion in a patient being evaluated for a benign tumor. The lesion is suspected to be one of hemangioma, focal nodular hyperplasia (FNH), or hepatocellular adenoma (HCA). The decision is to be justified by first-principles reasoning: compare the expected diagnostic benefit of biopsy against its expected harm, using the following fundamental bases rooted in surgical practice and clinical epidemiology.\n\nBase facts and definitions:\n- A hemangioma is a benign vascular malformation composed of blood-filled channels; its histology implies a higher bleeding risk with needle puncture compared with solid benign hepatocellular lesions.\n- Focal nodular hyperplasia (FNH) is a benign hyperplastic lesion with a central scar; it consists of normal hepatocytes with ductular reaction and abnormal vasculature, typically managed conservatively when confidently diagnosed.\n- Hepatocellular adenoma (HCA) is a benign hepatocellular tumor associated with estrogen exposure; it carries risks of hemorrhage and rare malignant transformation, and is often resected when size is large (for example, larger than $5~\\text{cm}$), in males, or when symptomatic.\n- Magnetic Resonance Imaging (MRI) can provide characteristic features for these lesions. When classic features are present, noninvasive diagnosis can approach near certainty, reducing the incremental value of biopsy.\n- Percutaneous liver biopsy carries a nonzero risk of hemorrhage that is higher in hemangioma due to its vascular structure. Tumor seeding risk is a significant concern for hepatocellular carcinoma (HCC) but is negligible for benign lesions such as FNH and HCA.\n- Decision-making can be framed by Bayesian updating of diagnostic probabilities from imaging and by a risk-benefit calculus in which expected harm is the probability of a complication multiplied by its disutility and expected benefit is the probability that biopsy changes management multiplied by the utility of that change.\n\nAssume the following empirically plausible test characteristics for MRI patterns (each evaluated against “not the target diagnosis” as the comparator class):\n- For the “classic hemangioma pattern” (peripheral nodular discontinuous enhancement with progressive centripetal fill-in and marked $T2$ hyperintensity): sensitivity $Se_H = 0.95$ and specificity $Sp_H = 0.98$.\n- For the “FNH pattern” using hepatobiliary agent uptake (iso- to hyperintensity on hepatobiliary phase, often with a central scar): sensitivity $Se_F = 0.90$ and specificity $Sp_F = 0.95$.\n- For the “adenoma pattern” (arterial phase hyperenhancement without hepatobiliary uptake, frequent intracellular fat with signal drop on opposed-phase, and lack of a central scar): sensitivity $Se_A = 0.85$ and specificity $Sp_A = 0.90$.\n\nAssume representative pretest probabilities in women aged $20$–$40$ years with an incidentally discovered solitary hypervascular lesion: $p(H) = 0.40$, $p(F) = 0.35$, and $p(A) = 0.25$, where $H$ denotes hemangioma, $F$ denotes FNH, and $A$ denotes HCA. For percutaneous biopsy, assume the probability of a major hemorrhage conditional on the true diagnosis is $p(\\text{bleed}\\mid H) = 0.020$, $p(\\text{bleed}\\mid F) = 0.006$, and $p(\\text{bleed}\\mid A) = 0.010$. Let the qualitative utility of a biopsy that correctly changes management be $U_{\\text{diagnostic}} > 0$, and the disutility of a major bleed be $C_{\\text{bleed}} > 0$.\n\nConsider the following scenarios and select the option(s) that correctly justify whether percutaneous biopsy is appropriate or contraindicated:\n\nA. A $45$-year-old woman has a $3.5~\\text{cm}$ lesion with classic hemangioma MRI features. Her pretest probability of hemangioma is $p(H) = 0.50$ (other causes collectively $p(\\neg H) = 0.50$). The clinician is considering biopsy to “be sure.” The question is whether biopsy is justified given the expected diagnostic gain relative to the expected harm from hemorrhage based on the lesion’s vascular nature.\n\nB. A $28$-year-old woman has a $6.0~\\text{cm}$ hypervascular lesion with arterial hyperenhancement but without hepatobiliary uptake; however, the MRI lacks definitive features to distinguish between FNH and HCA. Pretest probabilities are $p(F) = 0.50$ and $p(A) = 0.50$. Because management diverges substantially (conservative for FNH versus consideration of resection for HCA at $> 5~\\text{cm}$), the clinician considers biopsy to guide management, having corrected the International Normalized Ratio (INR) to $1.5$, stopped aspirin for $7$ days, and planned a coaxial technique to minimize passes.\n\nC. A $35$-year-old woman has a $3.0~\\text{cm}$ lesion with FNH-characteristic uptake on hepatobiliary phase MRI and a visible central scar; pretest $p(F) = 0.40$ (others $0.60$). She is asymptomatic. The clinician debates biopsy versus observation.\n\nD. A $32$-year-old man has a $4.0~\\text{cm}$ hypervascular lesion suspected to be HCA. The team states that biopsy is contraindicated due to “tumor seeding risk inherent to all hypervascular lesions,” and therefore should be avoided even if imaging remains indeterminate.\n\nWhich options correctly justify when percutaneous biopsy is appropriate or contraindicated in these scenarios?\n\nOptions:\nA. Contraindicated: classic hemangioma features on MRI yield near-certainty; expected harm from hemorrhage outweighs negligible diagnostic gain.\n\nB. Appropriate: indeterminate imaging between FNH and HCA at $6.0~\\text{cm}$ where diagnosis will change management; with bleeding risk mitigated, expected benefit exceeds expected harm.\n\nC. Contraindicated: FNH diagnosis is near-certain on hepatobiliary MRI; biopsy offers minimal incremental value and carries nonzero bleeding risk.\n\nD. Appropriate: biopsy should be avoided for suspected HCA because tumor seeding risk is intrinsic to all hypervascular lesions, including benign tumors, making biopsy broadly contraindicated.", "solution": "The problem statement is internally consistent, scientifically grounded in the principles of medical decision-making, and well-posed. All the necessary data and definitions are provided to analyze the scenarios. The problem is valid.\n\nThe analysis of each scenario and its corresponding option is as follows:\n\n**Analysis of Scenario A and Option A**\n\nThe scenario describes a $45$-year-old woman with a $3.5~\\text{cm}$ lesion showing \"classic hemangioma MRI features.\" The pretest probability of hemangioma is given as $p(H) = 0.50$. The provided MRI test characteristics for a classic hemangioma pattern are sensitivity $Se_H = 0.95$ and specificity $Sp_H = 0.98$. A positive test result ($T^+$) corresponds to observing these classic features. We can calculate the post-test probability of hemangioma using Bayes' theorem:\n\n$p(H \\mid T^+) = \\frac{p(T^+ \\mid H) \\cdot p(H)}{p(T^+ \\mid H) \\cdot p(H) + p(T^+ \\mid \\neg H) \\cdot p(\\neg H)}$\n\nHere, $p(T^+ \\mid H) = Se_H = 0.95$, and $p(T^+ \\mid \\neg H) = 1 - Sp_H = 1 - 0.98 = 0.02$. The pretest probabilities are $p(H) = 0.50$ and $p(\\neg H) = 0.50$.\n\n$$ p(H \\mid T^+) = \\frac{(0.95)(0.50)}{(0.95)(0.50) + (0.02)(0.50)} = \\frac{0.475}{0.475 + 0.01} = \\frac{0.475}{0.485} \\approx 0.9794 $$\n\nThe post-test probability of the lesion being a hemangioma is approximately $98\\%$, which is considered near-certainty in a clinical context. The management for a $3.5~\\text{cm}$ asymptomatic hemangioma is conservative observation. The probability that the lesion is not a hemangioma is $p(\\neg H \\mid T^+) \\approx 1 - 0.9794 = 0.0206$, or about $2\\%$. Even in this small chance, a small ($ 5~\\text{cm}$) FNH or HCA would also typically be managed with observation. Thus, the probability that a biopsy will change management is negligible.\n\nThe expected benefit of a biopsy, which is proportional to the probability of changing management, is therefore extremely small.\n\nThe expected harm is related to the probability of a major hemorrhage from the biopsy, $p(\\text{bleed})$. This is dominated by the high probability that the lesion is a hemangioma, which has the highest conditional bleeding risk:\n$p(\\text{bleed}) = p(\\text{bleed} \\mid H)p(H \\mid T^+) + \\dots \\approx p(\\text{bleed} \\mid H)p(H \\mid T^+) = (0.020)(0.9794) \\approx 0.0196$.\nThe expected harm is $p(\\text{bleed}) \\times C_{\\text{bleed}} \\approx 0.0196 \\cdot C_{\\text{bleed}}$, which is a non-negligible risk of a serious complication.\n\nComparing the two, the negligible expected benefit of biopsy is outweighed by the expected harm. Therefore, biopsy is contraindicated.\n\nOption A states: \"Contraindicated: classic hemangioma features on MRI yield near-certainty; expected harm from hemorrhage outweighs negligible diagnostic gain.\" This aligns perfectly with the analysis.\n\nVerdict for Option A: **Correct**.\n\n**Analysis of Scenario B and Option B**\n\nThis scenario involves a $28$-year-old woman with a $6.0~\\text{cm}$ lesion, where MRI is indeterminate between FNH and HCA. The pretest probabilities are $p(F) = 0.50$ and $p(A) = 0.50$. The management for these two conditions diverges significantly. An FNH is managed conservatively. An HCA of this size ($> 5~\\text{cm}$) is typically recommended for resection due to increased risks of hemorrhage and malignant transformation.\n\nThe decision to resect versus observe hinges directly on the definitive diagnosis. Therefore, a biopsy that can distinguish FNH from HCA has a very high diagnostic utility. The probability that the biopsy will change management is high; it is essentially the probability of clarifying the diagnosis, which in a $50/50$ scenario, is almost certain to dictate the final plan. So, the expected benefit, $p(\\text{change management}) \\cdot U_{\\text{diagnostic}}$, is substantial.\n\nThe expected harm is the probability of a major bleed, $p(\\text{bleed})$, multiplied by its disutility $C_{\\text{bleed}}$. We calculate the overall probability of a bleed based on the pretest probabilities:\n$$ p(\\text{bleed}) = p(\\text{bleed} \\mid F)p(F) + p(\\text{bleed} \\mid A)p(A) $$\n$$ p(\\text{bleed}) = (0.006)(0.50) + (0.010)(0.50) = 0.003 + 0.005 = 0.008 $$\nThe overall risk of a major bleed is $0.8\\%$. The scenario also notes that bleeding risk is being actively mitigated (correcting coagulopathy, stopping antiplatelets, using a coaxial technique). This further reduces the expected harm.\n\nIn this case, the substantial expected benefit (clarifying a critical management decision between major surgery and observation) clearly outweighs the low ($0.8\\%$) and mitigated expected harm of the procedure. Biopsy is therefore appropriate.\n\nOption B states: \"Appropriate: indeterminate imaging between FNH and HCA at $6.0~\\text{cm}$ where diagnosis will change management; with bleeding risk mitigated, expected benefit exceeds expected harm.\" This reasoning is sound and matches the analysis.\n\nVerdict for Option B: **Correct**.\n\n**Analysis of Scenario C and Option C**\n\nThis scenario describes a $35$-year-old woman with a $3.0~\\text{cm}$ lesion showing characteristic features of FNH on MRI (\"FNH-characteristic uptake on hepatobiliary phase... and a visible central scar\"). The pretest probability is $p(F) = 0.40$. The MRI test characteristics for an FNH pattern are $Se_F = 0.90$ and $Sp_F = 0.95$. A positive test result ($T^+$) corresponds to observing these classic features. We calculate the post-test probability of FNH:\n\n$p(F \\mid T^+) = \\frac{p(T^+ \\mid F) \\cdot p(F)}{p(T^+ \\mid F) \\cdot p(F) + p(T^+ \\mid \\neg F) \\cdot p(\\neg F)}$\n\nHere, $p(T^+ \\mid F) = Se_F = 0.90$, and $p(T^+ \\mid \\neg F) = 1 - Sp_F = 1 - 0.95 = 0.05$. The pretest probabilities are $p(F) = 0.40$ and $p(\\neg F) = 0.60$.\n\n$$ p(F \\mid T^+) = \\frac{(0.90)(0.40)}{(0.90)(0.40) + (0.05)(0.60)} = \\frac{0.36}{0.36 + 0.03} = \\frac{0.36}{0.39} \\approx 0.923 $$\n\nThe post-test probability of FNH is approximately $92\\%$, which is very high. The management for a $3.0~\\text{cm}$ asymptomatic FNH is observation. Given the high certainty of the diagnosis and the small size of the lesion, management is extremely unlikely to change with a biopsy result. The incremental diagnostic value is minimal.\n\nThe expected harm is the non-zero risk of a bleed from the biopsy. The approximate risk is:\n$p(\\text{bleed}) \\approx p(\\text{bleed} \\mid F)p(F \\mid T^+) = (0.006)(0.923) \\approx 0.0055$.\nSo the expected harm is approximately $0.0055 \\cdot C_{\\text{bleed}}$.\n\nAs in scenario A, the expected benefit is negligible, while the expected harm, though small, is non-zero. The risk-benefit analysis does not favor biopsy. Biopsy is contraindicated.\n\nOption C states: \"Contraindicated: FNH diagnosis is near-certain on hepatobiliary MRI; biopsy offers minimal incremental value and carries nonzero bleeding risk.\" This is a correct summary of the clinical reasoning.\n\nVerdict for Option C: **Correct**.\n\n**Analysis of Scenario D and Option D**\n\nThe scenario concerns a $32$-year-old man with a $4.0~\\text{cm}$ lesion suspected to be HCA. The team's justification for contraindicating biopsy is the \"tumor seeding risk inherent to all hypervascular lesions.\"\n\nThis justification is factually incorrect, as stated directly in the problem's \"Base facts and definitions\": \"Tumor seeding risk is a significant concern for hepatocellular carcinoma (HCC) but is negligible for benign lesions such as FNH and HCA.\" The concern about seeding applies to malignancies, not benign tumors, regardless of their vascularity. An HCA is a benign tumor. Therefore, the team's reasoning is scientifically unsound.\n\nIn a male patient, an HCA of any size is often resected due to a higher risk of malignant transformation compared to HCAs in female patients. Confirming the diagnosis is therefore of high importance. If imaging is indeterminate, biopsy is a critical tool to differentiate HCA (which would prompt surgery) from FNH (which would be observed). Contraindicating biopsy based on a fallacious argument about seeding risk is incorrect clinical practice.\n\nOption D states: \"Appropriate: biopsy should be avoided for suspected HCA because tumor seeding risk is intrinsic to all hypervascular lesions, including benign tumors, making biopsy broadly contraindicated.\" This option presents a conclusion and a justification. The justification provided (\"tumor seeding risk is intrinsic to all hypervascular lesions, including benign tumors\") is a false statement. Because the reasoning is fundamentally flawed, the option cannot be a \"correct justification.\"\n\nVerdict for Option D: **Incorrect**.\n\nIn summary, Options A, B, and C provide correct justifications for the appropriateness or contraindication of biopsy in their respective scenarios. Option D provides an incorrect justification based on a scientifically false premise.", "answer": "$$\\boxed{ABC}$$", "id": "4603363"}, {"introduction": "Beyond static measurements of size, a tumor's growth kinetics offer a dynamic window into its biological behavior and potential for future risk. This practice challenges you to quantify the growth of a hepatocellular adenoma using a first-principles mathematical model based on serial imaging data. This exercise [@problem_id:4603383] demonstrates how calculating a specific growth rate can transform clinical surveillance from passive observation into a proactive tool for timing surgical intervention before high-risk thresholds are crossed.", "problem": "A $32$-year-old woman with a biopsy-proven hepatocellular adenoma is followed with serial imaging. Magnetic Resonance Imaging (MRI) shows that the largest lesion’s diameter increased from $3.5~\\text{cm}$ to $4.6~\\text{cm}$ over $9$ months. For early-phase tumor kinetics in benign liver tumors, assume the lesion maintains an approximately spherical shape and that its volume $V(t)$ follows first-order growth with a constant specific rate, that is, the instantaneous rate of change of volume is proportional to the current volume. Using the geometric relationship between the volume of a sphere and its diameter and the definition of a constant specific growth rate, derive the annualized specific volumetric growth rate $k$ (in per year) of this adenoma from first principles based on the given measurements. Then, explain qualitatively how such a calculated growth rate could inform timing of resection decisions in hepatocellular adenoma, taking into account standard surgical principles for hemorrhage and malignant transformation risk.\n\nCompute and report $k$ as a single number in per year. Use time $t$ in years, treat the lesion as a sphere, and round your numerical answer to four significant figures. Express the growth rate in the unit per year; do not include any other unit in the final boxed value.", "solution": "The problem is assessed to be valid as it is scientifically grounded, well-posed, and objective. It provides a complete and consistent set of data for a realistic clinical scenario, allowing for a unique solution to be derived from first principles.\n\nThe solution is approached in two parts. First, the annualized specific volumetric growth rate $k$ is derived and calculated. Second, the clinical implications of this calculated rate are discussed.\n\n**Part 1: Derivation and Calculation of the Specific Volumetric Growth Rate ($k$)**\n\nThe problem states that the tumor's volume, $V(t)$, follows first-order growth kinetics. This means the instantaneous rate of change of volume with respect to time, $\\frac{dV}{dt}$, is directly proportional to the current volume $V$. This relationship is expressed by the differential equation:\n$$\n\\frac{dV}{dt} = kV\n$$\nwhere $k$ is the constant specific volumetric growth rate, with units of time$^{-1}$. To find the volume as a function of time, we solve this differential equation by separation of variables.\n$$\n\\frac{dV}{V} = k \\, dt\n$$\nWe integrate both sides between an initial state $(t_1, V_1)$ and a final state $(t_2, V_2)$:\n$$\n\\int_{V_1}^{V_2} \\frac{1}{V} \\, dV = \\int_{t_1}^{t_2} k \\, dt\n$$\nSince $k$ is a constant, the integration yields:\n$$\n[\\ln|V|]_{V_1}^{V_2} = [kt]_{t_1}^{t_2}\n$$\n$$\n\\ln(V_2) - \\ln(V_1) = k(t_2 - t_1)\n$$\nUsing the property of logarithms, $\\ln(a) - \\ln(b) = \\ln(a/b)$, and defining the time interval as $\\Delta t = t_2 - t_1$, we get:\n$$\n\\ln\\left(\\frac{V_2}{V_1}\\right) = k \\Delta t\n$$\nSolving for the specific growth rate $k$:\n$$\nk = \\frac{1}{\\Delta t} \\ln\\left(\\frac{V_2}{V_1}\\right)\n$$\nThe problem assumes the lesion is spherical. The volume $V$ of a sphere is related to its diameter $D$ by the formula:\n$$\nV = \\frac{4}{3}\\pi r^3 = \\frac{4}{3}\\pi \\left(\\frac{D}{2}\\right)^3 = \\frac{\\pi}{6}D^3\n$$\nThe initial volume $V_1$ corresponds to the initial diameter $D_1$, and the final volume $V_2$ corresponds to the final diameter $D_2$.\n$$\nV_1 = \\frac{\\pi}{6}D_1^3\n$$\n$$\nV_2 = \\frac{\\pi}{6}D_2^3\n$$\nThe ratio of the final volume to the initial volume is therefore:\n$$\n\\frac{V_2}{V_1} = \\frac{\\frac{\\pi}{6}D_2^3}{\\frac{\\pi}{6}D_1^3} = \\left(\\frac{D_2}{D_1}\\right)^3\n$$\nSubstituting this ratio into the expression for $k$:\n$$\nk = \\frac{1}{\\Delta t} \\ln\\left(\\left(\\frac{D_2}{D_1}\\right)^3\\right)\n$$\nUsing the logarithm property $\\ln(x^a) = a \\ln(x)$, we simplify the expression for $k$ to:\n$$\nk = \\frac{3}{\\Delta t} \\ln\\left(\\frac{D_2}{D_1}\\right)\n$$\nThis is the final analytical expression for the annualized specific volumetric growth rate based on diameter measurements.\n\nNow, we substitute the given numerical values.\nThe initial diameter is $D_1 = 3.5~\\text{cm}$.\nThe final diameter is $D_2 = 4.6~\\text{cm}$.\nThe time interval is $\\Delta t = 9$ months.\nThe problem requires an annualized rate, so we must express $\\Delta t$ in years.\n$$\n\\Delta t = 9 \\, \\text{months} \\times \\frac{1 \\, \\text{year}}{12 \\, \\text{months}} = \\frac{9}{12} \\, \\text{years} = 0.75 \\, \\text{years}\n$$\nSubstituting these values into the equation for $k$:\n$$\nk = \\frac{3}{0.75} \\ln\\left(\\frac{4.6}{3.5}\\right)\n$$\n$$\nk = 4 \\ln\\left(\\frac{4.6}{3.5}\\right)\n$$\nCalculating the numerical value:\n$$\nk \\approx 4 \\times \\ln(1.3142857...)\n$$\n$$\nk \\approx 4 \\times 0.273295...\n$$\n$$\nk \\approx 1.09318... \\, \\text{year}^{-1}\n$$\nRounding to four significant figures as required:\n$$\nk \\approx 1.093 \\, \\text{year}^{-1}\n$$\n\n**Part 2: Qualitative Explanation of Clinical Implications**\n\nThe calculated annualized specific volumetric growth rate $k \\approx 1.093 \\, \\text{year}^{-1}$ provides crucial quantitative information that informs clinical decision-making regarding the management of this hepatocellular adenoma (HCA). The management of HCAs balances the risks of expectant observation (hemorrhage, malignant transformation) against the risks of surgical resection.\n\nStandard surgical principles indicate that the risks associated with HCAs increase significantly with size. A diameter greater than $5~\\text{cm}$ is a widely accepted threshold at which the risks of spontaneous hemorrhage and malignant transformation into hepatocellular carcinoma (HCC) become substantial, often warranting prophylactic resection. The lesion in question, with a diameter of $4.6~\\text{cm}$, is approaching this critical size threshold.\n\nThe calculated growth rate $k$ adds a dynamic dimension to this risk assessment. A value of $k \\approx 1.093 \\, \\text{year}^{-1}$ is a very high growth rate, indicating that the tumor's volume is increasing by approximately $109.3\\%$ per year. Such rapid growth is a significant and concerning finding for several reasons:\n\n$1$. **Time to Reach High-Risk Size:** A high $k$ value implies that the lesion will reach the $5~\\text{cm}$ high-risk threshold in a short period. The calculation provides a quantitative basis to project this timeline, arguing against a prolonged 'wait and see' approach.\n\n$2$. **Indicator of Biological Aggressiveness:** Rapid proliferation, as quantified by a high $k$, may be an independent predictor of adverse outcomes. It can signal underlying molecular pathways associated with a more aggressive phenotype, potentially increasing the risk of malignant transformation even before the lesion reaches the $5~\\text{cm}$ mark. Some evidence suggests that a high growth rate is a more specific marker for malignant potential than absolute size alone.\n\n$3$. **Informing Timing of Resection:** For a $32$-year-old woman with a life expectancy of many decades, leaving a rapidly growing tumor in situ poses a cumulative long-term risk. The calculation of a high $k$ value provides strong, objective evidence to support a recommendation for earlier surgical resection rather than continued surveillance. It shifts the risk-benefit analysis, making the risks of expectant management appear greater than the procedural risks of a planned, elective hepatectomy. Therefore, this calculated growth rate would likely lead a surgeon to recommend resection sooner rather than waiting for the lesion to definitively cross the $5~\\text{cm}$ threshold.", "answer": "$$\\boxed{1.093}$$", "id": "4603383"}, {"introduction": "Once the decision for a major hepatectomy is made, the surgeon's primary responsibility shifts to ensuring the patient's safety and preventing post-operative complications. The most critical factor in this planning is guaranteeing a sufficient Future Liver Remnant (FLR) to sustain life after resection. This fundamental exercise [@problem_id:4603352] will have you perform the essential calculation of the FLR fraction, a non-negotiable step in the preoperative workup for any major liver resection.", "problem": "A patient with a symptomatic benign hepatic lesion is scheduled for resection. The lesion is consistent with a hepatocellular adenoma on imaging and biopsy, with features distinguishing it from focal nodular hyperplasia (FNH) and cavernous hemangioma. The mass extensively involves the right liver and segment $IV$, requiring an extended right hepatectomy (removal of segments $IV$–$VIII$), leaving only the left lateral section (segments $II$–$III$) as the Future Liver Remnant (FLR).\n\nPreoperative computed tomography volumetry reports a total liver volume of $1500~\\text{mL}$ and a left lateral section volume of $450~\\text{mL}$. The patient has normal liver function, no chronic liver disease, no steatosis, and no prior chemotherapy.\n\nUsing fundamental definitions relevant to post-hepatectomy planning in general surgery for benign liver tumors (hemangioma, FNH, adenoma), compute the FLR fraction as the ratio of remnant liver volume to total liver volume. Then, based on widely accepted thresholds for avoiding post-hepatectomy liver failure in non-fibrotic livers (where adequate FLR is generally $\\geq 0.20$), determine whether the planned resection is volumetrically adequate.\n\nExpress the FLR as a decimal fraction, rounded to three significant figures. Do not use a percentage sign.", "solution": "The problem statement will first be validated for scientific soundness, completeness, and objectivity.\n\n**Step 1: Extract Givens**\nThe following data and definitions are explicitly provided in the problem statement:\n-   Procedure: Extended right hepatectomy (removal of liver segments $IV$–$VIII$).\n-   Future Liver Remnant (FLR): Left lateral section (segments $II$–$III$).\n-   Total Liver Volume ($V_{\\text{total}}$): $1500~\\text{mL}$.\n-   Future Liver Remnant Volume ($V_{\\text{FLR}}$): $450~\\text{mL}$.\n-   Patient Liver Condition: Normal liver function, no chronic liver disease, no steatosis, no prior chemotherapy (collectively, a non-fibrotic or healthy liver).\n-   Definition of FLR fraction ($f_{\\text{FLR}}$): The ratio of remnant liver volume to total liver volume.\n-   Threshold for adequacy in non-fibrotic livers: Adequate FLR fraction is $\\geq 0.20$.\n-   Required output format: FLR fraction as a decimal rounded to three significant figures.\n\n**Step 2: Validate Using Extracted Givens**\n-   **Scientifically Grounded:** The problem is grounded in established principles of hepatobiliary surgery and preoperative planning. The concepts of liver segmentation (Couinaud segments), total liver volume, future liver remnant volume, and the FLR fraction are fundamental in assessing the risk of post-hepatectomy liver failure (PHLF). The given volumes are anatomically and physiologically realistic for an adult. The threshold of an FLR fraction of $0.20$ (or $20\\%$) is a widely accepted minimum for patients with healthy, non-cirrhotic livers. The distinction made between different benign liver tumors and the patient's liver health status is clinically relevant. The problem is scientifically sound.\n-   **Well-Posed:** The problem is well-posed. It provides all necessary numerical data ($V_{\\text{total}}$ and $V_{\\text{FLR}}$), a clear definition for the quantity to be calculated ($f_{\\text{FLR}}$), and a specific criterion for evaluation (the $0.20$ threshold). A unique, stable, and meaningful solution can be determined.\n-   **Objective:** The problem is stated using objective, standard medical and mathematical terminology. It is free of subjective claims or ambiguity.\n\n**Step 3: Verdict and Action**\nThe problem is valid. It is scientifically sound, well-posed, and objective. The solution process may proceed.\n\n**Solution**\nThe primary task is to compute the Future Liver Remnant (FLR) fraction, denoted as $f_{\\text{FLR}}$, and then to compare this value against a given clinical threshold.\n\nThe problem defines the FLR fraction as the ratio of the remnant liver volume to the total liver volume. Let $V_{\\text{FLR}}$ represent the future liver remnant volume and $V_{\\text{total}}$ represent the total liver volume. The formula for the FLR fraction is:\n$$f_{\\text{FLR}} = \\frac{V_{\\text{FLR}}}{V_{\\text{total}}}$$\n\nThe given values are:\n-   $V_{\\text{FLR}} = 450~\\text{mL}$\n-   $V_{\\text{total}} = 1500~\\text{mL}$\n\nSubstituting these values into the formula:\n$$f_{\\text{FLR}} = \\frac{450}{1500}$$\n\nThis fraction can be simplified by dividing both the numerator and the denominator by their greatest common divisor. We can start by dividing by $10$:\n$$f_{\\text{FLR}} = \\frac{45}{150}$$\nNow, we can divide by $15$:\n$$f_{\\text{FLR}} = \\frac{45 \\div 15}{150 \\div 15} = \\frac{3}{10}$$\n\nConverting this fraction to a decimal gives:\n$$f_{\\text{FLR}} = 0.3$$\n\nThe problem requires this result to be expressed as a decimal fraction rounded to three significant figures. The calculated value $0.3$ has only one significant figure. To express it with three significant figures, we must add trailing zeros after the decimal point:\n$$f_{\\text{FLR}} = 0.300$$\n\nThe second part of the task is to determine if the planned resection is volumetrically adequate. The threshold for adequacy in a patient with a normal, non-fibrotic liver is given as an FLR fraction greater than or equal to $0.20$.\nWe must compare the calculated FLR fraction with this threshold:\n$$f_{\\text{FLR}} \\geq 0.20$$\n$$0.300 \\geq 0.20$$\n\nThis inequality is true. Since the calculated FLR fraction of $0.300$ exceeds the minimum required threshold of $0.20$, the planned extended right hepatectomy is considered volumetrically adequate for this patient, implying a lower risk of post-hepatectomy liver failure. The final numerical answer requested is the FLR fraction expressed as a decimal rounded to three significant figures.", "answer": "$$\\boxed{0.300}$$", "id": "4603352"}]}